+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 118 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called TFC-003 in adults diagnosed with primary open-angle glaucoma or ocular hypertension. This phase 3 study aims to compare TFC-003 with other similar drug formulations to understand their impact on eye pressure, which is critical in managing these eye conditions. Participants will receive one of three treatments TFC-003 administered twice daily as eye drops, TFC-003-R1 also given twice daily, or a combination of two eye drops, TFC-003-R2 and TFC-003-R3, both given twice daily with at least a 10-minute gap between them. The treatments are given approximately at 830 AM and 830 PM each day. Each participant will be randomly assigned to one of these treatment groups in a parallel study design. During the study, participants will have their intraocular pressure measured at the start and at weekly intervals up to 24 weeks. The main outcome is the change in eye pressure over 12 weeks, with additional assessments extending to 24 weeks. Participants will be monitored closely through scheduled visits to ensure adherence to the treatment and to evaluate safety and effectiveness throughout the study period.

Age: 19Years +All GendersPhase 3
1 location
P

Actively Recruiting

Researchers are investigating new treatments for advanced renal cell carcinoma RCC that has returned after prior therapy. The study aims to find out if the combination of belzutifan and zanzalintinib can help people with recurrent advanced RCC live longer without their cancer worsening compared to the drug cabozantinib. This is a phase 3 randomized trial evaluating these treatments in participants who have experienced recurrence during or after prior anti-PD-1L1 therapy. Participants are randomly assigned to receive either belzutifan plus zanzalintinib taken orally once daily or cabozantinib taken orally once daily. They continue their assigned treatment until certain reasons require stopping the study intervention. The study compares the effects of these treatments on cancer progression and survival among people with advanced RCC who have had disease recurrence after adjuvant therapy. During the study, participants will be regularly monitored for progression-free survival and overall survival for up to about 73 months. Researchers will also assess tumor response, duration of response, adverse events, and quality of life using questionnaires over approximately 25 months. The study involves ongoing evaluations to understand how these treatments affect symptoms, functioning, and overall health during long-term follow-up.

Age: 18Years +All GendersPhase 3
127 locations
A

Actively Recruiting

Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.

Age: 18Years +All GendersPhase 3
206 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
P

Actively Recruiting

Researchers are evaluating VVD-130037, a Kelch-like ECH Associated Protein 1 KEAP1 activator, in adults with advanced solid tumors in a first-in-human study. The study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity of VVD-130037, both alone and combined with other cancer treatments. This is an open-label, phase 1 trial sponsored by Vividion Therapeutics, Inc., focusing on patients whose cancer has progressed despite prior standard therapies. Participants receive escalating doses of VVD-130037 orally once or twice daily in 21- or 28-day treatment cycles. In Part 1 dose escalation, VVD-130037 is tested alone and combined with intravenous docetaxel, paclitaxel, or pembrolizumab at established schedules. Part 2 dose expansion administers VVD-130037 at the recommended dose for expansion RDE, alone or in combination, to further evaluate safety and activity. Treatment cycles vary by combination, with docetaxel given every 3 weeks and paclitaxel given on days 1, 8, and 15 of each cycle. Participants undergo regular assessments including monitoring for dose-limiting toxicities during the first treatment cycle and tracking adverse events over up to 4 years. Laboratory tests, electrocardiograms, and imaging evaluations measure drug concentrations, heart rhythm, and tumor response. Researchers also evaluate overall response rates, duration of response, progression-free survival, and disease control rates. Safety follow-up and detailed pharmacokinetic studies are part of the long-term observation to understand the effects of VVD-130037 and its combinations.

Age: 18Years +All GendersPhase 1
26 locations
P

Actively Recruiting

Researchers are evaluating DA-3501, an investigational drug, in patients with advanced gastric or gastro-esophageal junction adenocarcinoma and advanced pancreatic ductal adenocarcinoma that express the CLDN18.2 protein. This first-in-human phase IIIa study aims to find the maximum tolerated dose MTD or optimal biological effective dose OBED of DA-3501 when given every three weeks, to determine the best recommended dose for further studies. Participants will receive DA-3501 intravenously once every three weeks at assigned dose levels. The study includes multiple dose levels, starting from dose level 1, to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy. Tumor assessments and various safety and laboratory tests will be performed according to the study schedule. During the study, participants will undergo tumor evaluations using standardized criteria, safety monitoring including dose-limiting toxicities during the first 21-day cycle, pharmacokinetic and immunogenicity testing, and overall response rate assessments. The study duration depends on treatment cycles and ongoing assessments. Safety and disease status will be monitored throughout, with follow-up continuing as per protocol until study end in February 2029.

Age: 19Years +All GendersPhase 1
3 locations
P

Actively Recruiting

Researchers are conducting a Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetics, and initial effectiveness of APX-343A alone and in combination with pembrolizumab in adults with advanced solid tumors. This study aims to better understand how these treatments behave in the body and their potential effects in this patient group. The study has two parts Part A tests increasing doses of APX-343A by itself, while Part B tests increasing doses of APX-343A together with pembrolizumab. APX-343A is given orally twice daily, and pembrolizumab is administered intravenously. Participants receive the assigned treatment to assess safety and determine appropriate doses. Participants will be monitored from enrollment through 90 days after treatment ends to evaluate safety and tolerability. Researchers will also measure drug levels in the body during the first three weeks and assess tumor response over about one year. The study involves regular assessments including tumor biopsies, imaging, and health status evaluations to track outcomes and effects.

Age: 19Years +All GendersPhase 1
3 locations
R

Actively Recruiting

Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.

Age: 12Years +All GendersPhase 3
148 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination of two investigational drugs, avutometinib and defactinib, compared to standard treatments chosen by doctors in patients with recurrent low-grade serous ovarian cancer LGSOC who have progressed after prior platinum-based therapy. This Phase 3, international, randomized, open-label study aims to compare progression-free survival and also assess overall survival, safety, quality of life, and disease symptoms. The study is conducted by specialists in gynecological cancer. Participants will receive either the combination of avutometinib and defactinib or one of four standard treatments recommended for recurrent LGSOC. Avutometinib is given orally at 3.2 mg twice weekly for 21 days followed by 7 days off in a 28-day cycle, combined with defactinib given orally at 200 mg twice daily on the same schedule. The standard treatments include pegylated liposomal doxorubicin, paclitaxel, anastrozole, or letrozole, each administered according to their usual dosing schedules. Patients initially receiving standard treatment who experience disease progression may switch to the investigational drug combination. During the study, participants will have regular visits for treatment and follow-up assessments including laboratory tests and evaluations of tumor status. Researchers will monitor progression-free survival for up to 24 months and overall survival for up to 5 years. They will also assess response rates, duration of response, disease control, adverse events, blood drug levels, and quality of life using questionnaires. The total study duration may extend until 2031, with ongoing monitoring of health and symptoms throughout.

Age: 18Years +FEMALEPhase 3
105 locations
P

Actively Recruiting

Researchers are evaluating the drug brenipatide compared to a placebo to see if it works and is safe for adults with Alcohol Use Disorder AUD and hazardous alcohol use. This phase 3 study aims to understand how brenipatide affects drinking patterns over time. Participation in this trial will last about 56 weeks, with careful monitoring throughout. Participants will receive brenipatide or placebo through subcutaneous injections. The study includes escalating doses of brenipatide administered under the skin. Participants must self-inject the study drug or receive assistance from a trained support person if needed. The treatment phase is structured in parallel groups, comparing the drug against placebo. During the study, participants will attend regular visits and be asked to maintain study diaries and complete questionnaires. Researchers will assess changes in drinking patterns using the Timeline Followback Method, daily alcohol consumption, alcohol cravings, and health outcomes such as body weight and quality of life. Blood samples will be collected to measure brenipatide levels and monitor for any immune responses. The study includes safety monitoring and lasts for approximately 56 weeks.

Age: 18Years - 75YearsAll GendersPhase 3
115 locations

1-10 of 118

1